It is important that cardiac troponin be measured accurately with a robust method to limit false results with potentially adverse clinical outcomes. In this study, we characterized the robustness of 4 analytical platforms by measuring the outlier rate between duplicate results.
cardiac troponin in blood, as well as its characteristic rise and fall, are key to the diagnosis of acute coronary syndrome (1) (2) (3) . Cardiac troponin concentrations can be increased in a number of pathological conditions other than acute coronary syndromes, as discussed in a recent review (4 ) . In parallel with other immunoassays, cardiac troponin assays may be subject to interference by heterophile antibodies, rheumatoid factor, and antitroponin autoantibodies (5) (6) (7) . Reports of spurious false cardiac troponin results on different analytical platforms have been published (8, 9 ) . False cardiac troponin results are a well-recognized clinical hazard, and the US Food and Drug Administration (FDA) has published a document to assist laboratories in dealing with this issue (10 ) . It is therefore important that cardiac troponin be measured accurately with a robust method.
We reported a lack of robustness in a cardiac troponin assay characterized by an unexpectedly high rate of outliers (11 ) . The outliers we described occurred erratically, were irreproducible, were not explicable by imprecision, and indicated a lack of robustness of the analytical system. Clinicians should be aware of these inaccuracies when interpreting results. The aim of this study was to investigate and compare the robustness of 4 contemporary cardiac troponin platforms.
Materials and Methods

STUDY DESIGN
We measured cardiac troponin in duplicate with 4 analytical platforms on routine samples submitted for cardiac troponin testing. From 8881 consecutive requests for cardiac troponin, 2418 samples had sufficient volume to be included in the study. We excluded the results from 27 samples because duplicate results were not obtained on all 4 analyzers. In the group of 2391 samples, there were 1800 unique patients, with 419 patients being sampled twice and 82 sampled 3 or more times during the study.
Samples were collected in serum separator tubes (Greiner Vacuette™, Greiner Bioone), centrifuged at 3000g for 10 min, and stored at 4°C after the routine cTn assay (Beckman AccuTnI reagent on a Beckman Unicell Dxi800 or Access2, Beckman Coulter Diagnostics). Provided sufficient sample was available for duplicate analysis on all 4 instruments, we analyzed the primary tube samples in a daily batch without any manipulation or recentrifugation of the sample. Each batch was divided into 4 subsets and analyzed concurrently on all 4 analyzers on a rotational basis. The median, minimum, and maximum time intervals between collection and analysis were 7.4, 3.2, and 19.5 h, respectively. After analysis, an aliquot was stored at Ϫ80°C and if an outlier was detected, the relevant sample was thawed and centrifuged before reanalysis in a single batch at the completion of the trial.
ANALYSIS
We measured cardiac troponin on the following platforms with their respective quoted performance characteristics. All reagents were obtained in a single delivery from each vendor between July and August 2010:
(1) Abbott Architect i2000SR analytical system with STAT Troponin-I reagent (Abbott Diagnostics), which has an analytical sensitivity of 0.01 g/L, a 10% CV at 0.032 g/L, and a 99th percentile of 0.028 g/L for an apparently healthy population (manufacturer's data); (2) Beckman Coulter Access2 analyzer with Enhanced AccuTnI reagent (reagent part number A78803, Beckman Coulter Diagnostics), which has an analytical sensitivity of 0.01 g/L and a 99th percentile of 0.040 g/L (manufacturer's data); (3) Roche Cobas e601 with TroponinT hs reagent (Roche Diagnostics), which has a limit of detection of 0.005 g/L, 10% CV at 0.013 g/L, and a 99th percentile of 0.0135 g/L (12 ); and (4) Siemens ADVIA Centaur XP with TnI-Ultra reagent (Siemens Healthcare Diagnostics), which has a limit of detection of 0.009 g/L, a total CV of 9.6% at 0.033 g/L, and a 99th percentile of 0.04 g/L (13 ) .
We used the 3 levels of the MAS CardioImmune XL (Microgenics) QC material on the Architect i2000SR and Access2 analyzers (CXL1205L, CXL12052, and CXL12053). Bio-Rad Liquichek Cardiac Markers Plus Control LT level 1 (Bio-Rad) replaced the low MAS CardioImmune Control on the Advia Centaur XP, and we used PreciControl Troponin TN1 and TN2 controls on the Cobas e601 analyzer for cTnT. We used the 99th percentile cardiac troponin concentration values as provided by the manufacturers as cutoff levels. Laboratory-derived precision data were used in the statistical definition and identification of outliers.
STATISTICAL ANALYSIS
Precision on each platform was determined according to NCCLS Guideline EP5-A2, with 1 set of QC performed in duplicate each day of the trial (14 ) . The limit of quantification (LOQ 20% ) for each analytical system was estimated from intermediate imprecision data (within-device or within-laboratory imprecision) as the lowest concentration that could be assayed with a CV of 20%.
Outliers were identified as described with minor modifications (11 ) . The estimated SD (SD est ) for each result was calculated by linear interpolation from the intermediate imprecision QC data. Results below the lowest QC level were assumed to have an SD est equal to that QC level, and results above the highest QC level were assumed to have a CV est equal to that QC level. We calculated a z value for each duplicate pair: z ϭ (result 1 Ϫ result 2) Ϭ ͌(SD1 est 2 ϩ SD2 est 2 ). A z value Ͼ3.48 was used to identify outliers between duplicate results at a probability of 0.0005. Results below the LOQ 20% were deemed to be equivalent to the LOQ 20% before calculating the z value.
In addition to the intermediate imprecision QC data method above, we also calculated the SDs and z values from the imprecision data obtained from duplicate analysis of patient samples after exclusion of outliers. Last, we calculated z values by assuming a constant SD equivalent to a 10% CV at the 99th percentile for lower values and a 10% CV for higher values.
Statistical comparison between analytical platforms was performed with the number of outliers observed between duplicate results. To estimate the clinical impact of outliers, we calculated the outlier rate as the number of outliers observed with singlet measurements. Data analysis and statistical procedures were performed with SPSS v.17 software. All percentages are reported with the 95% CI, and statistical testing was performed at the 5% significance level (P Ͻ 0.05).
Results
Of the 2391 samples in the data set, 862 (36%) had a routine cTnI result greater than the Beckman Coulter 99th percentile, 296 (12%) had a result Ͼ0.5 g/L, and 109 (5%) were Ͼ5.0 g/L. The imprecision data from QC material obtained over the duration of the trial is summarized in Table 1 , together with the imprecision data obtained from duplicate testing on patient samples in the closest corresponding bin. The imprecision data from patient sample duplicates compared well with the QC duplicates except at the lowest level, where the Cobas e601 and ADVIA Centaur XP demonstrated higher imprecision with patient samples. The precision profiles obtained from duplicate analysis of patient samples are presented in Fig. 1 . The Architect i2000SR exceeded a 10% CV at a mean cardiac troponin concentration of 0.028 g/L, the Access2 at 0.032 g/L, the Cobas e601 at 0.004 g/L, and the ADVIA Centaur XP at 0.061 g/L.
The duplicate cardiac troponin results for each analytical system are plotted in Fig. 2 , with the outliers identified by the QC intermediate imprecision data indicated by triangles. The number of outliers detected with the various permutations for calculating the z value is summarized in Table 2 . The 3 outliers observed on the Cobas e601 platform were not significantly different from the statistically expected frequency of 1.196 ( 2 ϭ 2.7, P ϭ 0.10), in contrast to the number of outliers on all the other platforms ( Table 2 ). The 5 outliers on the Architect i2000SR and ADVIA Centaur XP were, however, not significantly different from that observed on the Cobas e601 ( 2 ϭ 0.5, P ϭ 0.73). The 21 outliers observed on the Access2 were significantly higher than the 3 observed on the Cobas ( 2 ϭ 13.6, P ϭ 0.0002) and the 5 observed on both the Architect i2000SR and ADVIA Centaur XP ( 2 ϭ 9.9, P ϭ 0.0017). The 0.88% (0.51%-1.25%) outliers between duplicates observed with Enhanced AccuTnI reagent on the Access2 were not significantly different from the 1.25% (0.52%-1.98%) obtained with a previous version of the reagent ( 2 ϭ 0.91, P ϭ 0.34) (11 ) .
The results from all 4 analyzers on which an outlier was detected are presented in Table 3 ; in only 1 sample was an outlier observed in 2 methods (Architect i2000SR and ADVIA Centaur XP). The results of the repeat testing are presented in Table 4 . Repeat testing was not possible in 1 case because of insufficient sample, and in most cases the higher result of the pair was identified as the probable error. No outliers were detected in more than 1 sample from any individual in this cohort.
The outlier rate for singlet measurements, as de- (0.00%-0.13%), and ADVIA Centaur XP TnI-Ultra 0.10% (0.01%-0.19%).
Discussion
Spurious cardiac troponin results occur, but little is known about the extent of the problem on different analytical systems. We characterized outlier occurrence on 4 commonly used platforms by concurrently assaying 2391 samples in duplicate. Visual inspection of Fig. 2 provides information on the frequency of outliers across platforms, the magnitude of their deviations, and which outliers can be expected to have a clinical impact. Inspection of the graphs identifies the effect of imprecision on dispersion of results around the mean across the analytical range. The 5 outliers on the Architect i2000SR STAT Troponin-I system were visually distinct from the bulk of results that demonstrated a tight dispersion even below the 99th percentile decision level. The ADVIA Centaur XP TnI-Ultra had higher replicate imprecision at low levels of cardiac troponin, with patient samples compared with QC material (CV 9.5% at 0.059 g/L and 13.5% at 0.044 g/L on patient samples compared to 5.6% at 0.055 g/L on QC material), and this may indicate that imprecision with patient samples contributed to outliers on this platform as opposed to failure of the analytical system. The dispersion of duplicate results and the number of outliers on the Access2 were similar to those reported for an earlier reagent formulation (11 ) .
The Cobas e601 TroponinT hs demonstrated low imprecision between duplicates at all concentrations, and we identified 1 outlier that could potentially have affected patient care. The other 2 outliers identified above the 99th percentile were unlikely to be of clinical significance (0.026 vs 0.022 g/L and 0.041 vs 0.046 g/L respectively) ( Tables 3 and 4 ). The identification of these small differences as outliers is a function of the low imprecision of the assay and statistical probability, as one would expect approximately 1.196 result pairs to have a z value Ͼ3.48 from a sample this size.
The identification of outliers depended on both the imprecision data used to estimate the SD and then calculate the z value and the z value chosen as the decision level. In this and our previous study (11 ), we arbitrarily defined outliers as statistically rare events where the difference between duplicates exceeded that expected in Ͻ0.05% of cases (P Ͻ 0.0005, z Ͼ 3.48). We estimated the SD of the results from interpolated and extrapolated intermediate QC imprecision data, which included longer-term variation and would be expected to have higher imprecision than that obtained with duplicates. The use of short-term imprecision from duplicates will theoretically be a better estimate of imprecision to calculate z values and detect outliers. However, this resulted in an apparent increase in outliers on all platforms that appeared to have little clinical relevance ( Table 2) . A potential disadvantage of using both short-and medium-term imprecision data to identify outliers is that clinically insignificant differences between results may be classified as outliers on a platform with low imprecision. To compare the platforms with identical criteria, and to relate the detection of outliers to a desirable performance requirement, we also used a fixed 10% CV that resulted in a decrease of apparent outliers in all methods except the ADVIA Centaur XP TnI-Ultra (Table 2 ). In the latter, the additional outliers at low cardiac troponin concentrations were detected as a consequence of higher imprecision with patient samples (imprecision with patient samples less than a cTnI of 0.061 g/L resulted in a CV above 10%). Increasing the z value threshold will raise the specificity of the procedure to detect outliers that are both statistically and clinically significant. From Tables 3  and 4 , it is apparent that using the QC intermediate imprecision and choosing a z value Ͼ 5 (probability of an event occurring is 1 in 1.75 million), the number of outliers with Architect i2000SR was 5, 14 with Access2, 2 with Cobas e601, and 3 with ADVIA Centaur XP. In contrast, a constant 10% CV and a z value Ͼ 5 identified 4 apparent outliers with Architect i2000SR, 17 with Access2, 1 with Cobas e601, and 3 with ADVIA Centaur XP (data not shown). This conservative approach identified outliers that may have a significant clinical impact and corresponded to the most extreme outliers in Fig. 2 . The outlier rates for single measurements with this methodology were 0.11% (0.02%-0.20%) with the Architect i2000SR STAT Troponin-I, 0.36% (0.19%-0.53%) with the Access2 Enhanced AccuTnI, 0.02% (0.00%-0.06%) with the Cobas e601 TroponinT hs, and 0.06% (0.00%-0.13%) with the ADVIA Centaur XP TnI-Ultra. The numbers of outliers detected with the variations above were significantly higher than the Recently published recommendations on the use of cardiac troponin attributed rare transient falsepositive results to fibrin strands without providing a source reference; we suspect that these are similar to the outliers we have described (15 ) . The exact cause of the outliers we described is not known, but the errors occurred spuriously, were irreproducible, and could be detected by reanalyzing the sample without recentrifuging. Robustness of analytical systems may reside in the hardware and/or the reagent composition, and it may vary between individual analyzers and reagent batches. Variation in local conditions (e.g., sample quality, laboratory environment) may have an effect on the outlier rate irrespective of the robustness of the analytical system. The sample type used in this study was serum, and although a different sample type (e.g., heparin plasma) may theoretically affect outlier rate, we have demonstrated that there is no statistically significant difference between serum and plasma (11 ) . It is important to note that the findings of this study represent the results on single analyzers at 1 site only.
The critical nature of cardiac troponin testing in patients with the acute coronary syndrome has highlighted the impact of outliers in our laboratory. Few data exist regarding outlier rates, but one would expect outliers to occur with most laboratory tests and on all platforms at a rate dependent on the inherent robustness of the analytical system.
We focused on outliers found between duplicate results and not on discordant results between the different analytical platforms. The latter occurred infrequently and would require a different approach to identify and manage. This is currently being investigated as part of a comprehensive correlation study.
In this study, we demonstrated that outliers occur in 4 contemporary cardiac troponin assays, albeit at significantly different rates. Although it is obvious that low outlier rates are preferable, each laboratory scientist and clinician will have to decide what is acceptable. We are of the view that the rates of all 4 assays are such that they can be used in clinical practice, with the proviso that the outlier rate is considered and managed appropriately. We further recommend that manufacturers define and strive to continuously improve the robustness of their assays.
